Credit Suisse Ag Atea Pharmaceuticals, Inc. Transaction History

Credit Suisse Ag

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	BUY	$3.0 - $4.97 $7,290 - $12,077	2,430 Added 3.27%	76,764 $257,000
Q4 2022 Feb 13, 2023	BUY	$4.35 - $6.17 $86,312 - $122,425	19,842 Added 36.41%	74,334 $357,000
Q3 2022 Nov 10, 2022	BUY	$5.49 - $8.79 $2,470 - $3,955	450 Added 0.83%	54,492 $310,000
Q2 2022 Aug 12, 2022	BUY	$5.33 - $8.18 $201,324 - $308,974	37,772 Added 232.16%	54,042 $383,000
Q1 2022 May 16, 2022	SELL	$5.5 - $9.19 $16,450 - $27,487	-2,991 Reduced 15.53%	16,270 $118,000
Q4 2021 Feb 14, 2022	BUY	$7.67 - $44.59 $14,289 - $83,071	1,863 Added 10.71%	19,261 $172,000
Q3 2021 Nov 12, 2021	BUY	$21.33 - $35.06 $115,608 - $190,025	5,420 Added 45.25%	17,398 $610,000
Q2 2021 Aug 16, 2021	BUY	$19.22 - $59.08 $230,217 - $707,660	11,978 New	11,978 $257,000

112

52.4M

900

126K

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $270M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.